2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

2:30PM-4:00PM: Abstract Number: 883

The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Ankylosing Spondylitis: A General Population-Based Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I

2:30PM-4:00PM: Abstract Number: 843

The Role of Personality in Patients with Fibromyalgia

ARHP Psychosocial Impact on Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 896

The Steroid Tapering in ANCA Vasculitis Evaluation Study (STAVE) 2: A Systematic Review and Meta-Analysis

Vasculitis I: Clinical Trials and Outcomes

2:30PM-4:00PM: Abstract Number: 880

Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels: Results from a Phase 3 Clinical Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I

2:30PM-4:00PM: Abstract Number: 856

Trends and Predictors of Chronic Opioid Use in Individuals with RA

Pain – Basic and Clinical Aspects Oral

2:30PM-4:00PM: Abstract Number: 849

Tumor TIF1 Mutations and Loss of Heterozygosity Related to Cancer Associated Myositis

Muscle Biology, Myositis and Myopathies

2:30PM-4:00PM: Abstract Number: 873

Type I High-IFN Gene Signature in Associated with Higher Essdai at Enrollmment and Follow-up in the Prospective Multicenter Assess Cohort of 395 Patients

Sjögren's Syndrome I: Clinical Assessment and Trial Outcomes

2:30PM-4:00PM: Abstract Number: 839

Use of Bisphosphonate and Risk of Incident Atrial Fibrillation in a Population-Based Study

Epidemiology and Public Health I: Lung, Bone, and Infection Outcomes

2:30PM-4:00PM: Abstract Number: 881

Ustekinumab Is Superior to TNF Inhibitor Treatment in Resolving Enthesitis in Psa Patients with Active Enthesitis- Results from the Enthesial Clearance in Psoriatic Arthritis Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I

2:30PM-4:00PM: Abstract Number: 869

Utility of Carotid Ultrasound Compared to Framingham Risk Score in Predicting Cardiovascular Mortality in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects I: Cardiac Comorbidities

4:30PM-6:00PM: Abstract Number: 938

A Germline Macrophage Activation Syndrome-Associated Nlrc4 Mutation Causes Chronic, Systemic, Non-Hematopoietic IL-18 Elevation and Intestinal MHC-II Upregulation

Pediatric Rheumatology – Pathogenesis and Genetics

4:30PM-6:00PM: Abstract Number: 906

Anp32a Is a Critical Regulator of Oxidative Stress in Cartilage and Protects Against Osteoarthritis

Biology and Pathology of Bone and Joint

4:30PM-6:00PM: Abstract Number: 948

Application of a Diagnostic Algorithm to Identify Inflammatory Myopathy in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics I

4:30PM-6:00PM: Abstract Number: 920

Area-Level Predictors of Medication Nonadherence Among U.S. Medicaid Beneficiaries with Lupus: A Multilevel Study

Healthcare Disparities in Rheumatology

4:30PM-6:00PM: Abstract Number: 932

Association of Varus Knee Thrust during Walking to Worsening Knee Pain over Two Years

Osteoarthritis – Clinical Aspects I: Pain and Functional Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].